Noticias de CSTL_US

Noticias del mercado

Últimas noticias sobre CSTL_US — 66 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.

Ticker: CSTL_US ✕ 66 resultados
09/04/2026 CSTL_US — Investing.com
Castle Biosciences CEO sells shares worth $246,195 By Investing.com
08/04/2026 CSTL_US — Stock Titan
Strong 2025 revenue and governance focus in Castle Biosciences (CSTL) proxy
08/04/2026 CSTL_US — Investing.com
Castle Biosciences CEO sells shares worth $246,195
08/04/2026 CSTL_US — Stock Titan
Castle Biosciences (CSTL) CEO pre-planned sale of 9,836 shares after option exercise
08/04/2026 CSTL_US — MarketBeat
Insider Selling: Castle Biosciences (NASDAQ:CSTL) Insider Sells 6,214 Shares of Stock
08/04/2026 CSTL_US — Investing.com
Castle Biosciences CEO sells shares worth $246,195 By Investing.com
08/04/2026 CSTL_US — Stock Titan
[ARS] CASTLE BIOSCIENCES INC SEC Filing
31/03/2026 CSTL_US — Stock Titan
CSTL SEC Filings - Castle Biosciences 10-K, 10-Q, 8-K Forms
30/03/2026 CSTL_US — Stock Titan
Castle Biosciences (CSTL) CEO executes 10b5-1 share sales, exercises options
30/03/2026 CSTL_US — Seeking Alpha
Castle Biosciences: Buying The Remaining DecisionDx-Melanoma Upside (NASDAQ:CSTL)
30/03/2026 CSTL_US — Stock Titan
Director at Castle Biosciences (CSTL) acquires 5,329 shares via RSUs
30/03/2026 CSTL_US — Investing.com
Castle Biosciences CEO Maetzold sells shares worth $106,598
29/03/2026 CSTL_US — Stock Traders Daily
(CSTL) Movement as an Input in Quant Signal Sets
27/03/2026 CSTL_US — Yahoo Finance
Castle Biosciences' DecisionDx®-Melanoma Test Significantly Improves Risk Prediction Within AJCC Stages to Support Personalized, Risk-Aligned Management of Cutaneous Melanoma, Data to Be Presented at AAD 2026
27/03/2026 CSTL_US — Investing.com
Castle Biosciences presents melanoma test data at AAD meeting
27/03/2026 CSTL_US — Stock Titan
Castle test splits same-stage melanoma patients by 5-year survival odds
27/03/2026 CSTL_US — Newswise ES ← EN
La prueba DecisionDx®-Melanoma de Castle Biosciences mejora significativamente la predicción de riesgos dentro de las etapas del AJCC para respaldar el manejo personalizado y alineado con los riesgos del melanoma cutáneo; los datos se presentarán en la AAD 2026

La prueba DecisionDx®-Melanoma de Castle Biosciences mejora significativamente la predicción de riesgos dentro de las etapas del AJCC para respaldar el manejo personalizado y alineado con los riesgos del melanoma…

26/03/2026 CSTL_US — Stock Titan
Vanguard realigns reporting; holds 0% of Castle Biosciences (CSTL)
26/03/2026 CSTL_US — Stock Titan
Derek Maetzold reports multiple Rule 144 sales — CSTL (CSTL)
23/03/2026 CSTL_US — Seeking Alpha
Castle Biosciences, Inc. (CSTL) Discusses Clinical Utility and Evidence Supporting DecisionDx Melanoma Test and DECIDE Study - Slideshow (NASDAQ:CSTL) 2026-03-23

Página 2 de 4

keyboard_arrow_up